SkinHealth Systems Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SKIN research report →
Range $10 – $14
Price Chart
About the company
SkinHealth Systems Inc. , a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums.
- CEO
- Pedro Malha
- IPO
- 2020
- Employees
- 613
- HQ
- Long Beach, CA, US
Get TickerSpark's AI analysis on SKIN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $76.68M
- P/E
- -4.21
- Fwd P/E
- 20.29
- PEG
- 0.01
- P/S
- 0.27
- P/B
- 1.40
- EV/EBITDA
- 6.90
- Div Yield
- 0.00%
- Gross Margin
- 67.21%
- Op Margin
- 2.40%
- Net Margin
- -6.33%
- ROE
- -32.09%
- ROIC
- 2.14%
Latest fiscal year · YoY change
- Revenue
- $300.79M-10.0%
- Gross Profit
- $196.36M+7.7%
- Op Income
- $-20,803,000
- Net Income
- $-9,519,000+67.3%
- EPS
- $-1.60+65.2%
- OCF Growth
- +132.3%
- FCF Growth
- +246.1%
- 52W High
- $33.00
- 52W Low
- $9.68
- 50D MA
- $12.50
- 200D MA
- $15.58
- Beta
- 1.05
- RSI (14)
- 44
- Avg Volume
- 42.38K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SkinHealth Systems said Q3 showed a clear improvement in revenue trends, stronger margins, and early traction in consumables and new commercial initiatives, even as equipment sales and EMEA remained under pressure.· November 5, 2026
- Q3 revenue was $69.2 million, down 2.1% year over year, but the decline improved from 7.8% in Q2 and 6.7% in Q1.
- Consumables returned to growth, rising 1.2% overall; the Americas grew 1.4% and consumables there rose 4.3%.
- GAAP gross margin expanded to 68.2% from 64.6%, adjusted gross margin reached 71.8%, and adjusted EBITDA was $13.4 million.
- The company repaid the remaining $103.2 million principal of its 2026 convertible notes and ended Q3 with about $112.4 million in cash.
- Management raised full-year 2026 guidance for adjusted EBITDA to $48 million-$50 million, while net sales guidance narrowed to $281 million-$287 million.
Third-quarter 2026 net sales were $69.2 million, down 2.1% year over year. GAAP gross margin was 68.2% versus 64.6% a year ago; adjusted gross margin was 71.8% versus 68.0% last year. Income from operations was approximately $5 million versus an operating loss of $6.2 million in the prior year quarter, and net loss was approximately $0.9 million. Adjusted EBITDA was $13.4 million, or 19.3% of revenue, versus $8.9 million, or 12.6% a year ago. For Q4, management expects adjusted gross margin to moderate sequentially, with higher operating expenses and meaningfully higher R&D. Full-year 2026 guidance was updated to net sales of $281 million-$287 million and adjusted EBITDA of $48 million-$50 million, up from prior adjusted EBITDA guidance of $39 million-$46 million.
Pedro Malha framed the quarter as evidence that the business is stabilizing and operating from a stronger foundation, while stressing that execution is not yet complete. He pointed to better commercial discipline, stronger consumables momentum, and a broader strategy to get more value from the installed base through innovations like HydraScalp, boosters, and treatment enhancers. He also emphasized that the company is building beyond Hydrafacial with SkinStylus and another planned complementary device, while acknowledging that equipment sales, utilization, and EMEA remain weak spots.
Mike Monahan highlighted the financial improvements in Q3, including 68.2% GAAP gross margin, 71.8% adjusted gross margin, $13.4 million of adjusted EBITDA, and $10.2 million of free cash flow. He said Q3 margin improvement was helped by lower Elite trade-in costs, about $1 million of tariff refunds, improved inventory management, and a richer consumables mix, but noted Q4 gross margin should moderate as equipment mix rises and tariff benefits do not repeat. He also said the company repaid the remaining $103.2 million principal of its 2026 convertibles, ended with about $112.4 million in cash, and still has about $250 million of convertible debt due in Q4 2028 that it expects to address in 2027.
Analysts focused on whether consumables growth is durable, what is driving it, and how to think about system churn and the new rental program. Management said consumables strength came from better U.S. execution, signature consumables, HydraScalp relaunch activity, and the new HydraClear booster, while Mike said net churn was positive 59 units, helped by lower fall-off and dormant accounts returning. On EMEA, management said the region has improved from down 19% in Q2 to down 11.7% in Q3, but it remains pressured and needs better leadership, processes, and field execution; on the rental program, they said it is early, books revenue upfront, and carries slightly lower gross margin because the financing partner takes some economics and default risk.
The bull case from the call is that the revenue decline is narrowing, consumables are growing again, and margins are structurally better than a year ago. Management also sounded confident that new programs—rental, corporate accounts, HydraScalp, boosters, and SkinStylus—can extend the installed base’s productivity and create more recurring revenue over time.
The main bear case is that equipment demand is still weak, especially in EMEA, where management said capital decisions remain a barrier and sales cycles are longer. They also cautioned that Q4 gross margin should moderate, operating expenses and R&D will rise, and the company is still early in proving that new initiatives can offset continued pressure in the core equipment business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.6%
- Shares Outstanding
- 6.51M
- Float Shares
- 4.02M
of shares held by institutions
100 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SKIN, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.39M | ▼ 123.69K |
| Vanguard Group Inc | 5.67M | ▲ 68.78K |
| Fmr LLC | 5.48M | ▼ 4.73M |
| Millennium Management LLC | 5.02M | ▼ 2.52M |
| Vanguard Capital Management LLC | 3.50M | 0 |
| Woodline Partners LP | 1.94M | ▼ 386.59K |
| Silver Point Capital, L.P. | 1.59M | 0 |
| Geode Capital Management, LLC | 896.24K | ▼ 64.14K |
| Jane Street Group, LLC | 673.72K | ▲ 673.72K |
| D. E. Shaw & Co., Inc. | 655.48K | ▼ 776.83K |
| Glendon Capital Management LP | 636.95K | 0 |
| Prescott Group Capital Management, L.L.C. | 508.18K | ▼ 69.55K |
Held by 32 ETFs
Biggest fund positions in SKIN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 9, 26 | Malha Pedro Bruno Ferreira | other | 99,742 |
| Oct 9, 26 | Malha Pedro Bruno Ferreira | other | 78,045 |
| Aug 10, 26 | MONAHAN MICHAEL P. | other | 32,357 |
| Apr 17, 26 | BEATTIE EDWARD SCOTT | other | 0 |
| Apr 17, 26 | Shridharani Sachin Mahavir | other | 0 |
| Apr 17, 26 | Tripp Kenneth Robert | other | 0 |
| Apr 9, 26 | Lewis Sheri | other | 24,904 |
| Apr 9, 26 | MONAHAN MICHAEL P. | other | 26,776 |
| Mar 20, 26 | Malha Pedro Bruno Ferreira | other | 2,654,867 |
| Mar 20, 26 | MONAHAN MICHAEL P. | other | 746,681 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SKIN coverage
Recent articles, reports, and earnings notes.
No research on SKIN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SKIN report →Investing in SkinHealth Systems Inc. (SKIN)? Don't Miss Assessing Its International Revenue Trends
zacks.com · Nov 9
SkinHealth Systems Inc. (SKIN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 8
Beauty Health Q3 Earnings Call Highlights
marketbeat.com · Nov 6
SkinHealth Systems Inc. (SKIN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 5
SkinHealth Systems Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
SkinHealth Systems Inc. (SKIN) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com · Oct 29
SkinHealth Systems to Report Third Quarter 2026 Financial Results on November 5, 2026
globenewswire.com · Oct 22
SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock?
zacks.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.